Typical prices in 2026
No government agency publishes U.S. ketamine clinic prices. Most ranges below come from HealingMaps, a commercial ketamine clinic directory. By its own disclaimer, HealingMaps may be paid for reviews, endorsements, advertising, and affiliate links. It bases the ranges on its own clinic and inquiry data and does not publish its methodology. The Spravato® list price comes from the drugmaker's own state filings, and the Medicare row from Medicare. Confirm every price directly.
| Item | Typical range | Notes |
|---|---|---|
| IV infusion (psychiatric dose) | About $300–$800 per session (HealingMaps median $450) | Coastal metro clinics tend to run higher; some markets lower |
| IM (intramuscular) ketamine | About $200–$500 per session (HealingMaps median $350) | A shot into a muscle instead of an IV line; usually cash-pay |
| Initial IV series (6 infusions) | About $1,800–$4,800 (six infusions at that per-session range) | Many clinics discount packages; see caveat below |
| IV maintenance booster | About $300–$800 each | Commonly every 4–8 weeks for people who respond; budget for it |
| First year of IV ketamine (if you respond and keep going) | About $3,600–$14,400 (our estimate) | Our arithmetic, not a quoted price. 6 induction infusions plus 6–12 boosters (one every 4–8 weeks for the rest of the year), at $300–$800 each. See how many treatments |
| Spravato® (commercial insurance) | Copay varies by plan | Coverage depends on your plan's criteria; clinic observation fees may bill separately |
| Spravato® (no insurance) | 2026 list price: $895.10 per 56 mg treatment, $1,342.66 per 84 mg treatment | Drug only, before discounts. Not what you pay. The visit and 2-hour monitoring bill separately. Up from $590 and $885 at the 2019 launch |
| Spravato® (Original Medicare) | If Medicare covers it: the Part B deductible ($283 in 2026), then usually 20% of the Medicare-approved amount | Assumes the provider accepts Medicare's amount. Your regional Medicare contractor decides coverage. When the center supplies the drug, one code covers the visit, drug, and monitoring. Medicare Advantage may differ. See Spravato insurance coverage |
| Ketamine-assisted psychotherapy | About $400–$1,200 per session (HealingMaps median $650) | Driven by therapist time, not the drug |
| At-home compounded programs | About $200–$450/month | Cheapest and least supervised; see our safety page |
What one study found on IV prices
One peer-reviewed study offers a check on those numbers. In March 2023, researchers from Johns Hopkins and the University of Colorado reviewed the websites of 17 ketamine advertisers in Maryland. Seven of them posted a price for an infusion. Those prices ran from $360 to $2,500 per infusion. Some clinics charged different prices for different conditions. These were advertised prices, not bills, from one state and a small sample. Still, the low end falls inside the HealingMaps range, and the high end is more than three times its top figure. Get a written quote before you book.
What Spravato® costs without insurance
The most recent list price we found comes from the company itself. In a report dated April 30, 2026, to California’s Department of Health Care Access and Information, Janssen, the J&J company that makes Spravato®, gave the wholesale list price after a January 29, 2026 increase: $895.10 for the 56 mg dose kit and $1,342.66 for the 84 mg dose kit. Each kit holds one treatment: two 28 mg nasal spray devices for the 56 mg dose, three for the 84 mg dose. At launch in 2019 the same kits listed at $590 and $885, according to Janssen’s filing with the Vermont Attorney General’s office. That filing says the list price does not reflect discounts and rebates.
A list price is not a bill. It covers only the medicine. The treatment center also charges for the visit and for watching you for at least two hours afterward, which the label requires. If you plan to pay cash, ask the center for one quote that covers the drug, the visit, and the monitoring.
Why Spravato® is often covered and infusions usually aren't
FDA approval may make insurance coverage more likely. Whether a given plan pays still turns on its own rules: the diagnosis, medical-necessity criteria, prior authorization, and the treatment setting. Spravato® is FDA-approved for specific indications, which is why many plans have a coverage pathway for it. Generic IV ketamine for psychiatric conditions is used off-label. No manufacturer ever ran the FDA approval process for that use, so most plans have no coverage pathway at all. The practical rule: if insurance coverage is a requirement, start by asking about Spravato® and confirm your own plan's criteria before scheduling anything.
For infusions, some clinics can bill the evaluation, monitoring, or psychotherapy components to insurance even when the infusion itself is cash-pay. It's worth asking about explicitly. A few patients also succeed with out-of-network reimbursement using superbills. Success varies by plan.
For how Spravato® and IV ketamine compare beyond price, see Ketamine vs. Spravato. For the published Spravato rules of eight commercial insurers, Medicare, and East Coast Medicaid programs, see Spravato insurance coverage.
Coverage questions, answered briefly
Does Medicare cover ketamine infusions?
Do not count on it. IV ketamine for depression is used off-label, and infusions are usually cash-pay. Original Medicare can cover Spravato® given in a certified clinic, under Part B, through billing codes G2082 and G2083. Each code covers the visit, the medicine, and two hours of observation together, and the regional Medicare contractor decides whether to cover them. CMS lists the separate esketamine drug code, J0013, as not payable by Medicare. Our answer to Does Medicare cover Spravato®? has the details.
What does Spravato® cost per dose?
The wholesale list price, effective January 29, 2026, is $895.10 for a 56 mg treatment and $1,342.66 for an 84 mg treatment. That is the drug alone, before discounts. Outside Original Medicare’s combined codes, the visit and the two hours of monitoring usually bill separately. With insurance, your share depends on your plan. Our page on Spravato insurance coverage explains how plans decide.
Are there lower-cost ways to get Spravato®?
If you have commercial insurance, the manufacturer’s withMe Savings Program can lower the cost of the medicine to as little as $10 per treatment, up to an annual maximum. A separate Observation Rebate Program pays back eligible people’s out-of-pocket cost for the observation visit, up to an annual maximum, after they pay the provider. The rebate is not valid for residents of Massachusetts, Minnesota, or Rhode Island. Neither program is open to people using Medicare, Medicaid, or other government-funded coverage. The full terms are in our answer to Is there a savings program for Spravato®?
Questions to ask before paying anything
- What does the quoted price include: evaluation, the infusion, monitoring, follow-ups? What bills separately?
- Do you offer Spravato®, and will you handle the prior authorization?
- What's your maintenance protocol and its annual cost for a typical responder?
- What happens financially if I haven't responded by your planned reassessment point?
- Can you provide a superbill for out-of-network reimbursement?
- Do you accept HSA/FSA payment?
Ways people reduce the cost
The main options, in rough order of impact:
- Use Spravato® with insurance rather than cash-pay infusions when clinically appropriate.
- Compare several clinics in your metro. Prices vary widely for the same protocol.
- If you have commercial insurance, ask about the manufacturer's Spravato withMe savings program. It is not available to people using government insurance such as Medicare or Medicaid.
- Use HSA/FSA dollars.
- Ask whether evaluation and monitoring visits can be billed to insurance.
- Check for clinical trials at academic medical centers. According to ClinicalTrials.gov, many studies pay for the study treatment and research-related tests and visits, but you or your insurance still pay for your regular health care. Some trial participants receive placebo.
At a glance
- Budget roughly $300–$800 per IV infusion (HealingMaps median $450). That works out to about $1,800–$4,800 for a six-infusion series, plus ongoing maintenance.
- If you respond and keep going, a first year of IV ketamine works out to about $3,600–$14,400 at those prices (6 infusions plus 6–12 boosters).
- Spravato® is the insurance-friendly path. Many plans cover it with prior authorization, but coverage depends on your plan's criteria. On Original Medicare, if it is covered, you pay the Part B deductible, then usually 20%.
- Ask exactly what's included in any quote. Observation and follow-up fees are common surprises.
- Don't prepay six sessions before knowing whether you respond. Get refund terms in writing.
- HSA/FSA funds, superbills, copay programs, and clinical trials can all cut real dollars.
Sources
- HealingMaps (commercial ketamine clinic directory) — Ketamine Infusion Therapy Cost; estimates from its own clinic and inquiry data, updated May 2026, methodology not published — cash-pay price estimates
- Crane et al., "False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland," JAMA Network Open (2023) — advertised infusion prices in Maryland, 2023 — PubMed
- California Department of Health Care Access and Information (HCAI) — Prescription Drug WAC Increases, October 2026 monthly update (Janssen report dated April 30, 2026; NDCs 50458-0028-02 and -03) — Spravato 2026 list price
- Janssen Pharmaceuticals — Report to the Vermont Office of the Attorney General on introducing Spravato, submitted April 10, 2019 (18 V.S.A. § 4637) — Spravato 2019 launch list price (PDF)
- Johnson & Johnson (manufacturer) — SPRAVATO® Access, Coding and Reimbursement Guide, January 2026 — observation billed as a separate service (PDF)
- Johnson & Johnson (manufacturer) — SPRAVATO withMe Savings Program requirements, October 2025 — savings program terms (PDF)
- Johnson & Johnson (manufacturer) — SPRAVATO withMe Observation Rebate Program requirements, July 2025 — observation rebate terms, including the MA, MN and RI exclusion (PDF)
- CMS — October 2026 Alpha-Numeric HCPCS file (J0013, G2082, G2083 status) — J0013 not payable by Medicare (ZIP)
- CMS — CY 2020 Physician Fee Schedule final and interim final rules, HCPCS G2082 and G2083 for esketamine (interim final), 84 FR 63102–63104 (Nov. 15, 2019) — G2082 and G2083
- Medicare.gov — Medicare costs: Part B deductible and coinsurance — 2026 Part B deductible and coinsurance
- Anand et al., "Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression" (ELEKT-D), New England Journal of Medicine (2023) — response after six IV infusions — PubMed
- Spravato® (esketamine) Full Prescribing Information — Johnson & Johnson label (PDF)
- DailyMed (NLM) — Spravato® current prescribing information
- ClinicalTrials.gov (NIH) — Learn About Studies: costs, payment, and placebo — what studies pay for